Bank of America assumed coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report issued on Monday morning, 24/7 WallStreet reports. The firm issued a buy rating and a $19.00 price target on the stock.
Shares of FULC stock opened at $9.26 on Monday. Fulcrum Therapeutics has a 12 month low of $9.25 and a 12 month high of $15.94.
In other news, major shareholder 6 Dimensions Capital, L.P. bought 118,750 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $1,900,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mark J. Levin bought 81,250 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was purchased at an average price of $16.00 per share, with a total value of $1,300,000.00. The disclosure for this purchase can be found here.
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.
Featured Article: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.